News from CPhI

Aesica ramps up HPAPI capacity to meet industry demand

By Natalie Morrison

- Last updated on GMT

A fear of handling toxic compounds has led to a shortage of HP contracters, according to Aesica
A fear of handling toxic compounds has led to a shortage of HP contracters, according to Aesica
The technical challenge posed by potent APIs means drug industry demand for R&D-scale contract manufacturing is largely unmet, according to Aesica.

The UK contract manufacturing organisation (CMO) spoke to at CPhI, and said the observation was one driver behind its decision to invest in development-scale granulation and coating capacity at its facility in Nottingham.

The other, according to site manager Ian Lafferty, was the number of enquiries Aesica has received about capacity for high potency work at the site since it opened in May.

He said: We’ve had a number of enquiries about more difficult capabilities, such as granulation and we’ve shown we can build an isolator around this equipment and still operate them.

“For instance, fluid bed coating and fluid bed granulation are dusty processes, and doing that with a HP compound causes even more issues than with capsule filling. Doing it inside the isolators makes those issues go away.”

A growing need

Lafferty told us that a lack of highly potent (HP) contractors for R&D (research and development) stems from an unwillingness to deal with toxic products because of old stigmas associated with workers using suits, rather than the safer isolator technology as found in the Nottingham facility.

He said issues like finding staff willing to work with the molecules, the extra investments associated with handling them, and even hesitance from sponsors who fear working in HP facilities have also led to a shortage of vendors.

However with a growing industry need for innovation, and many HP pipelines left untouched because companies cannot find suitable partners to manufacture products for R&D, Lafferty said the need for providers has never been greater.

 “I do think this is a growing trend in the industry, but there are few places that offer the services. HP puts people off - it takes investment, and staff don’t want to work on it because of associated perception of danger,”​ he said.

He also said that for rare and orphan indications there is an opportunity for firms to work on the product commercially, as they need smaller – but higher value – batch sizes.

Related news

Show more

Related products

show more

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers